Characteristics and Outcomes of Severe Aplastic Anemia Patients Who Were Treated with Allogenic Hematopoietic Stemcell Transplantation at Institute Pediatric Hospital Kuala Lumpur during 2003-2012

Nur Suryawan^1, , Lelani Reniarti¹, Hishamshah Ibrahim² and Asohan Thevarajah²

¹Department of Child Health, Universitas Padjadjaran, Bandung, Indonesia

²Departement of Child Health, Institute Pediatrik Hospital Kuala Lumpur, Malaysia

Cite this paper

Nur Suryawan, Lelani Reniarti, Hishamshah Ibrahim and Asohan Thevarajah. Characteristics and Outcomes of Severe Aplastic Anemia Patients Who Were Treated with Allogenic Hematopoietic Stemcell Transplantation at Institute Pediatric Hospital Kuala Lumpur during 2003-2012. American Journal of Clinical Medicine Research. 2017; 5(2):15-19. doi: 10.12691/AJCMR-5-2-1

Abstract

Aplastic anemia is characterized by the development of peripheral blood pancytopenia associated with hypocellularity of the bone marrow. Treatment strategies for aplastic anemia include immunosupressive therapy and hematopoietic stemcell transplantation. The choice of therapy depends on the severity of the disease, patient’s age and availability of a human leukocyte antigen (HLA) matched sibling donor. To describe the clinical characteristics and outcomes of all patients diagnosed with severe aplastic anemia who were treated with allogenic hematopoietic stemcell transplantation at IPHKL. All patients with SAA who had underwent matched sibling hematopoietic stemcell transplantation at IPHKL from January 2002- December 2013 were identified. Retrospective data was collected with regards to patient’s characteristics, transfusion history, conditioning regime, time of engraftment, length of stay, complication and outcomes of patients. In this study there were 36 patients with SAA who underwent allogenic hematopoietic stemcell transplantation. Of the 36 patients, 20 (55.6%) were boys and 16 (44.4%) were girls. The most regimes used for conditioning was combination of fludarabine, cyclophosphamide and ATG horse in 19 patients (52.8%). Mostly the granulocyte engraftment at 10 days after transplantation, while platelet engraftment occurred at 12 days after transplantation. Complications that occurred after transplant were febrile neutropenia in 32 patients (88.9%), mucositis in 25 patients (69.4%), fungal infection in 4 patients (11.1%) and only 2 patients had GvHD. No patients died after underwent allogenic hematopoietic stemcell transplantation. Thirty four patients (94.4%) were cured after a single hematopoietic stemcell transplantation, and only 2 patients (5.6%) had late graft rejection, but all were cured after having the second transplantation The outcomes of patients with severe aplastic anemia who had underwent allogenic hematopoietic stemcell transplantation in bone marrow transplantation ward IPHKL were good. All patients were cured from the disease.

Keywords

severe aplastic anemia, allogenic hematopoietic stemcell transplantation

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Haematologica. 1994; 79:438-44.
[2]	Teo J, Dror Y. Aquired aplastic anemia. In: Arceci RJ, Hann IM, Smith OP, (eds). Pediatric Hematology. 3rd ed. Massachusetts: Blackwell Publishing; 2006. pp. 64-72.
[3]	Young NS. Acquired aplastic anemia. Ann Intern Med. 2002 Apr 2; 136(7): 534-46.
[4]	Young NS, Calado RT, Scheinberg P. Current concepts in pathophysiology and treatment of aplastic anemia. Blood. 2006; 108: 2509-17.
[5]	Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009Oct; 147(1):43-70.
[6]	Trigg ME. Hematopoietic stem cells. Pediatrics 2004; 113: 1051-57.
[7]	Hutspardol S, Sirachainan N, Anurathapan U, Pakakasama S, Songdej D, Chuansumrit A, et al. Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia. J Med Assoc Thai. 2013 Jan,96 suppl 1:S18-24.
[8]	Jalili M, Alimoghaddam K, Hamidieh AA, Hamdi A, Jahani M, Bahar B, et al. Hematopoietic stem cell transplantation in patients with severe acquired aplastic anemia: Iranian experience. IJHOSCR 2011 Oct; 5 (4):22-27.
[9]	Ustun C, Arslan O, Beksac M, Koc H, Gurman G, Ozcelik T, et all. A retrospective comparison of allogeneic peripheral blood stemcell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs-host disease and relapse. Biol Blood Marrow Transplant. 1999; 5: 28-35.
[10]	Liu YC, Chang CS, Liu TC, Chen TP, Sue YC, Hsiao HH, et al. Comparison between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience. Kaoshiung J Med Sci 2003 Nov; 19(11): 541-8.
[11]	Storb R, Leisenring W, Anasette C. Methotrexate and cyclosporine for graft vs host disease prevention: what length of therapy with cyclosporine. Biol Blood Marrow Transplant. 1997; 3: 194-201.
[12]	Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007 May; 109(10): 4582-85.
[13]	Chan KW, Li CK, Worth LL, Chick KW, Jeha S, Shing MK, et all. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant. 2001; 27: 125-8.
[14]	Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, et all. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transplant. 2010; 16: 1582-8.
[15]	Jones G, Clark J, Galloway A. Management of febrile neutropenia and system specific infectious. In: Cant AJ, Galloway A, Jackson G, (eds). Practical hematopoietic stem cell transplantation 1st ed. Massachusetts: Blackwell Publishing; 2007. pp. 92-107.
[16]	Guirado MA, Espigado I, Cordero E, Noquer M, Parody R, Pachon J, et all. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow transplant. 2010; 45: 159-64.
[17]	Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am. 2008; 52: 61-viii.
[18]	Mattsson J. Graft failure after allogeneic hematopoietic stemcell transplantation. Biol Blood Marrow Transplant. 2008; 14: 165-70.
[19]	Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004 Apr; 103(4): 2490-97.